About Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CAPR
CUSIPN/A
Phone310-358-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio9.41%
Quick Ratio9.41%
Price-To-Earnings
Trailing P/E Ratio-3.05
Forward P/E Ratio-3.20
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.67 million
Price / Sales13.95
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book3.05
Profitability
EPS (Most Recent Fiscal Year)($0.44)
Net Income$2.43 million
Net Margins91.15%
Return on EquityN/A
Return on Assets-87.67%
Miscellaneous
Employees40
Outstanding Shares27,710,000
Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How were Capricor Therapeutics' earnings last quarter?
Capricor Therapeutics Inc (NASDAQ:CAPR) announced its quarterly earnings data on Wednesday, March, 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01. The biotechnology company earned $0.48 million during the quarter, compared to analysts' expectations of $0.63 million. View Capricor Therapeutics' Earnings History.
When is Capricor Therapeutics' next earnings date?
What price target have analysts set for CAPR?
2 analysts have issued 12 month price targets for Capricor Therapeutics' shares. Their forecasts range from $2.15 to $9.00. On average, they expect Capricor Therapeutics' stock price to reach $5.5750 in the next twelve months. View Analyst Ratings for Capricor Therapeutics.
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include BioXcel Therapeutics (BTAI), Zynerba Pharmaceuticals (ZYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), Sierra Oncology (SRRA), Bellerophon Therapeutics (BLPH), Aeglea Bio Therapeutics (AGLE), Checkpoint Therapeutics (CKPT), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals (ADMP), Galectin Therapeutics (GALT), Affimed (AFMD), Cerecor (CERC), OncoMed Pharmaceuticals (OMED) and ContraFect (CFRX).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
- Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
- Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
- Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
- Deborah Ascheim M.D., Chief Medical Officer
- Joshua A. Kazam, Director (Age 40)
Has Capricor Therapeutics been receiving favorable news coverage?
Press coverage about CAPR stock has trended somewhat positive this week, Accern reports. Accern rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Capricor Therapeutics earned a media sentiment score of 0.21 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 43.94 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Capricor Therapeutics?
Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
One share of CAPR stock can currently be purchased for approximately $1.3441.
How big of a company is Capricor Therapeutics?
Capricor Therapeutics has a market capitalization of $37.97 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.44) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.
How can I contact Capricor Therapeutics?
Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]
MarketBeat Community Rating for Capricor Therapeutics (CAPR)
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Capricor Therapeutics (NASDAQ:CAPR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Capricor Therapeutics in the last 12 months. Their average twelve-month price target is $5.5750, suggesting that the stock has a possible upside of 314.78%. The high price target for CAPR is $9.00 and the low price target for CAPR is $2.15. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.5750 | $5.3750 | $4.3250 | $4.3250 |
| Price Target Upside: | 314.78% upside | 218.05% upside | 336.87% upside | 336.87% upside |
Capricor Therapeutics (NASDAQ:CAPR) Consensus Price Target History
Capricor Therapeutics (NASDAQ:CAPR) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Capricor Therapeutics (NASDAQ:CAPR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Capricor Therapeutics (NASDAQ CAPR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.50%
Institutional Ownership Percentage: 8.83%
Capricor Therapeutics (NASDAQ CAPR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/9/2017 | Louis Manzo | Director | Buy | 10,000 | $3.10 | $31,000.00 | 138,384 |  |
| 5/9/2017 | Sinai Medical Center Cedars | Major Shareholder | Buy | 1,145,161 | $3.10 | $3,549,999.10 | 4,049,959 | |
| 9/21/2016 | Sinai Medical Center Cedars | Major Shareholder | Buy | 312,500 | $3.20 | $1,000,000.00 | 2,904,798 | |
| 3/16/2016 | Anthony Bergmann | VP | Buy | 2,030 | $2.40 | $4,872.00 | 2,030 | |
| 3/16/2016 | Karen Krasney | EVP | Buy | 4,060 | $2.40 | $9,744.00 | 11,156 | |
| 3/16/2016 | Leland Gershell | CFO | Buy | 2,100 | $2.40 | $5,040.00 | 2,100 | |
| 3/16/2016 | Linda Marban | CEO | Buy | 10,152 | $2.40 | $24,364.80 | | |
| 3/16/2016 | Louis J Grasmick | Director | Buy | 91,369 | $2.40 | $219,285.60 | | |
| 3/16/2016 | Sinai Medical Center Cedars | Major Shareholder | Buy | 416,666 | $2.40 | $999,998.40 | 2,592,298 | |
| 8/20/2015 | Louis J. Grasmick | Director | Buy | 11,900 | $4.11 | $48,909.00 | 5,950 | |
| 8/19/2015 | Eduardo Marban | major shareholder | Buy | 18,400 | $4.36 | $80,224.00 | 3,173,354 | |
| 1/21/2015 | Joshua A Kazam | Director | Buy | 7,096 | $3.52 | $24,977.92 | | |
| 1/21/2015 | Sinai Medical Center Cedars | Major Shareholder | Buy | 851,546 | $3.52 | $2,997,441.92 | | |
(Data available from 1/1/2013 forward)
Capricor Therapeutics (NASDAQ CAPR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Wired News – Capricor’s New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy
finance.yahoo.com - April 23 at 8:15 AM |
 | Findings are the Basis for the HOPE-2 Clinical Trial
globenewswire.com - April 19 at 8:16 AM |
| Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
finance.yahoo.com - April 19 at 8:16 AM |
| Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
globenewswire.com - April 12 at 8:35 AM |
| Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
finance.yahoo.com - April 12 at 8:35 AM |
 | Capricor Therapeutics (CAPR) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 8 at 1:28 PM |
| Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018
finance.yahoo.com - April 6 at 5:41 PM |
| Capricor Therapeutics (CAPR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 4 at 6:54 PM |
 | Capricor Therapeutics (CAPR) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 5:30 PM |
| Capricor Therapeutics (CAPR) PT Set at $9.00 by HC Wainwright
www.americanbankingnews.com - March 29 at 11:16 AM |
| Capricor Therapeutics (CAPR) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 28 at 7:04 PM |
| Wired News – OPKO Health Announced Enrollment of First Patient in Phase-2b Trial of OPK88003 to Treat Type-2 Diabetes
finance.yahoo.com - March 27 at 8:27 AM |
| Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences - GlobeNewswire (press release)
globenewswire.com - March 21 at 8:48 AM |
| Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences
finance.yahoo.com - March 21 at 8:48 AM |
| Capricor Therapeutics (CAPR) versus Versartis (VSAR) Critical Contrast
www.americanbankingnews.com - March 16 at 5:22 AM |
| Capricor Therapeutics (CAPR) Posts Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - March 15 at 10:45 AM |
| Capricor Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 14 at 7:07 PM |
| Has Capricor Therapeutics Inc (NASDAQ:CAPR) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 14 at 7:07 PM |
| Earnings Preview For Capricor Therapeutics
finance.yahoo.com - March 14 at 7:07 PM |
| Capricor posts 4Q profit
finance.yahoo.com - March 14 at 7:07 PM |
| Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
finance.yahoo.com - March 14 at 7:07 PM |
| Capricor Therapeutics (CAPR) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 12 at 7:10 PM |
| Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:20 AM |
| Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14
finance.yahoo.com - March 8 at 6:44 PM |
| Capricor Therapeutics (CAPR) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 7 at 6:57 PM |
| Capricor Therapeutics (CAPR) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 6 at 7:00 PM |
| Capricor Therapeutics (CAPR) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM |
| Brown Advisory Inc. Buys New Stake in Capricor Therapeutics Inc (CAPR)
www.americanbankingnews.com - March 2 at 5:10 AM |
| Capricor to Host Key Opinion Leader Lunch on March 9 - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:15 AM |
| Capricor to Host Key Opinion Leader Lunch on March 9
finance.yahoo.com - February 28 at 8:17 AM |
| Report: Developing Opportunities within Tupperware Brands, Eaton Vance, Marcus & Millichap, Lockheed Martin, Coherus BioSciences, and Capricor Therapeutics — Future Expectations, Projections Moving into 2018
finance.yahoo.com - February 23 at 8:21 AM |
| New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
finance.yahoo.com - February 22 at 5:38 PM |
| Capricor Therapeutics (CAPR) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 14 at 7:12 PM |
| Capricor Therapeutics (CAPR) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 13 at 7:00 PM |
| Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
finance.yahoo.com - February 12 at 9:44 AM |
 | Pre-Open Movers 02/05: (CAPR) (EYES) (BG) Higher; (WFC) (DKS) (QCOM) Lower (more...)
www.streetinsider.com - February 5 at 3:40 PM |
| Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
finance.yahoo.com - February 5 at 3:40 PM |
 | BRIEF-Capricor Therapeutics Says FDA Has Granted CAP-1002 RMAT Designation
www.reuters.com - February 5 at 9:34 AM |
| Zacks Investment Research Downgrades Capricor Therapeutics (CAPR) to Hold
www.americanbankingnews.com - February 2 at 6:42 PM |
| Who Are Capricor Therapeutics Inc’s (NASDAQ:CAPR) Major Shareholders?
finance.yahoo.com - January 30 at 3:43 PM |
| Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - January 26 at 11:48 PM |
| Capricor Therapeutics Inc (CAPR) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - January 24 at 5:42 PM |
| Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
finance.yahoo.com - January 16 at 8:58 AM |
| Capricor Therapeutics Inc (CAPR) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 30 at 7:46 AM |
| Capricor Therapeutics (CAPR) versus Trevena (TRVN) Head to Head Review
www.americanbankingnews.com - December 29 at 9:30 AM |
| Market Trends Toward New Normal in Lockheed Martin, Silver Spring Networks, Capricor Therapeutics, Tupperware Brands, Eaton Vance, and Marcus & Millichap — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - December 18 at 8:58 AM |
| ETFs with exposure to Capricor Therapeutics, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:23 PM |
 | Capricor Therapeutics Announces Issuance of Key US Patent on Exosome Technology - PR Newswire (press release)
www.prnewswire.com - December 13 at 5:01 PM |
| BRIEF-Capricor Therapeutics Announces Issuance Of Key U.S. Patent On Exosome Technology
www.reuters.com - December 13 at 9:05 AM |
| Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology
finance.yahoo.com - December 13 at 9:05 AM |
Capricor Therapeutics (NASDAQ:CAPR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Capricor Therapeutics (NASDAQ:CAPR) Income Statement, Balance Sheet and Cash Flow Statement
Capricor Therapeutics (NASDAQ CAPR) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
